A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605

Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes

(2010) Mikkael A. Sekeres et al.   AMERICAN JOURNAL OF HEMATOLOGY

Angiopoietin-2 in CLL

(2010) J. A. Burger   BLOOD

Stress-induced premature senescence mediated by a novel gene, SENEX, results in an anti-inflammatory phenotype in endothelial cells

(2010) P. R. Coleman et al.   BLOOD

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia

(2010) T. A. Fehniger et al.   BLOOD

Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias

(2010) William Blum et al.   JOURNAL OF CLINICAL ONCOLOGY

CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT

(2009) C D Ford et al.   BONE MARROW TRANSPLANTATION

Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities

(2009) Farhad Ravandi et al.   CANCER

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

(2009) S. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

(2008) L. Ades et al.   BLOOD

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

(2008) Benjamin L. Ebert et al.   NATURE